Decoding molnupiravir-induced mutagenesis in SARS-CoV-2.
J Biol Chem
; 297(1): 100867, 2021 07.
Article
in English
| MEDLINE | ID: covidwho-1265746
ABSTRACT
Molnupiravir, a prodrug of the nucleoside derivative ß-D-N4-hydroxycytidine (NHC), is currently in clinical trials for COVID-19 therapy. However, the biochemical mechanisms involved in molnupiravir-induced mutagenesis had not been explored. In a recent study, Gordon et al. demonstrated that NHC can be incorporated into viral RNA and subsequently extended and used as template for RNA-dependent RNA synthesis, proposing a mutagenesis model consistent with available virological evidence. Their study uncovers molecular mechanisms by which molnupiravir drives SARS-CoV-2 into error catastrophe.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Cytidine
/
SARS-CoV-2
/
COVID-19
/
Hydroxylamines
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
J Biol Chem
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS